Citations

Showing 10 of 108104 citations.

Creating an Award-winning RSNA Education Exhibit
Albasha, Heba , Burkett, Brian J. , Sweet, David E. , Balthazar, Patricia , Burkett, Brian , Sweet, David

Mayo Clinic

RadioGraphics | April 1, 2022 | Volume: 42 | Issue: 4 | Pages: E106-E108

10.1148/rg.220048 | PMID 35363551 Get It

Editorial for “Myelin Water Imaging of Nerve Recovery in Rehabilitating Stroke Patients”
Raghavan, Sheelakumari , Reid, Robert I. , Reid, Robert I , Raghavan, Sheelakumari

Mayo Clinic

Journal of Magnetic Resonance Imaging | April 1, 2022 | Volume: 56 | Issue: 5 | Pages: 1557-1558

10.1002/jmri.28184 | PMID 35363900 Get It

Phase II Study of Selumetinib in Children and Young Adults With Tumors Harboring Activating Mitogen-Activated Protein Kinase Pathway Genetic Alterations: Arm E of the NCI-COG Pediatric MATCH Trial
Eckstein, Olive S. , Allen, Carl E. , Williams, P. Mickey , Roy‐Chowdhuri, Sinchita , Patton, David R. , Coffey, Brent , Piao, Jin , Saguilig, Lauren, Ramirez, Nilsa C. , Jaju, Alok , Mhlanga, Joyce , Fox, Elizabeth , Hawkins, Douglas S. , Mooney, Margaret , Takebe, Naoko , Tricoli, James V. , Janeway, Katherine A. , Seibel, Nita L. , Parsons, D. Williams , Reid, Joel M. , Piao, Jin , Ramirez, Nilsa C , Jaju, Alok I , Fox, Elizabeth , Hawkins, Douglas S , Takebe, Naoko , Janeway, Katherine A , Seibel, Nita L , Parsons, D Williams , Allen, Carl E , Roy-Chowdhuri, Sinchita , Patton, David R , Williams, P Mickey , Alonzo, Todd A. , Berg, Stacey L.

Mayo Clinic

Journal of Clinical Oncology | April 1, 2022 | Volume: 40 | Issue: 20 | Pages: 2235-2245

10.1200/jco.21.02840 | PMID 35363510 Get It

PURPOSE The NCI-COG Pediatric MATCH trial assigns patients age 1-21 years with relapsed or refractory solid tumors, lymphomas, and histiocytic disorders to phase II studies of molecularly targeted therapies on the basis of detection of predefined genetic alterations. Patients with tumors harboring mutations or fusions driving activation of the mitogen-activated protein kinase (MAPK) pathway were treated with the MEK inhibitor selumetinib. METHODS Patients received selumetinib twice daily for 28-day cycles until disease progression or intolerable toxicity. The primary end point was objective response rate; secondary end points included progression-free survival and tolerability of selumetinib. RESULTS Twenty patients (median age: 14 years) were treated. All were evaluable for response and toxicities. The most frequent diagnoses were high-grade glioma (HGG; n = 7) and rhabdomyosarcoma (n = 7). Twenty-one actionable mutations were detected: hotspot mutations in KRAS (n = 8), NRAS (n = 3), and HRAS (n = 1), inactivating mutations in NF1 (n = 7), and BRAF V600E (n = 2). No objective responses were observed. Three patients had a best response of stable disease including two patients with HGG ( NF1 mutation, six cycles; KRAS mutation, 12 cycles). Six-month progression-free survival was 15% (95% CI, 4 to 34). Five patients (25%) experienced a grade 3 or higher adverse event that was possibly or probably attributable to study drug. CONCLUSION A national histology-agnostic molecular screening strategy was effective at identifying children and young adults eligible for treatment with selumetinib in the first Pediatric MATCH treatment arm to be completed. MEK inhibitors have demonstrated promising responses in some pediatric tumors (eg, low-grade glioma and plexiform neurofibroma). However, selumetinib in this cohort with treatment-refractory tumors harboring MAPK alterations demonstrated limited efficacy, indicating that pathway mutation status alone is insufficient to predict response to selumetinib monotherapy for pediatric cancers.
The effectiveness of Tuina in managing chronic non-specific low back pain
Zhou, Xuan , Yang, Juan , Ma, Qingyu , Guo, Yu , He, Kejie , Shen, Longbin , Fan, Qiao , Philip, Cheong Kwok Chee, Keng, Tay Boon, Celia, Tan Ia Choo, Bauer, Brent A. , Chen, Jiaxu

Mayo Clinic

Medicine | April 1, 2022 | Volume: 101 | Issue: 7 | Pages: e28883

10.1097/md.0000000000028883 | PMID 35363203 Get It

Abstract Background: Chronic non-specific low back pain (CNLBP) is a common complaint about medical care and carries a heavy social burden. The efficacy of Tuina (TN) or physiotherapy (PT) for CNLBP has been evaluated in previous systematic reviews. However, there is no high-quality evidence to support the efficacy of Tuina. Therefore, this study aims to conduct a large-scale, multicenter, high-quality clinical trial to provide evidence for Tuina to treat CNLBP. Methods: This is a multicenter, assessor-, and analyst-blinded, randomized controlled trial with 3 parallel arms: TN, PT, and TN combined with PT (Tuina combined with physiotherapy) group. Six hundred twelve eligible CNLBP patients will be randomly assigned to the groups in a 1:1:1 ratio in 3 centers. The TN intervention includes 9-step routine techniques, while the PT intervention includes a physiotherapy treatment plan based on a patient's symptoms. The interventions for both groups will last for 30 minutes and will be carried out for 6 sessions in 8 weeks. The primary outcome will be the visual analog scale pain score. And the secondary outcomes will include the Oswestry Disability Index, spinal range of motion, 36-item short-form health survey. Safety evaluation will be recorded during the whole study. All data in this randomized controlled trial will be analyzed by SAS 9.4. Discussion: The results of this trial will provide evidence to evaluate the efficacy of Tuina's value as a treatment for CNLBP. Trial registration: Chinese Clinical Trial Registry (ChiCTR2000040288, November 27, 2020).
Targeted clearance of p21 ‐ but not p16 ‐positive senescent cells prevents radiation‐induced osteoporosis and increased marrow adiposity
Chandra, Abhishek , Lagnado, Anthony B. , Doolittle, Madison L. , Kirkland, James L. , LeBrasseur, Nathan K. , Robbins, Paul D. , Niedernhofer, Laura J. , Ikeno, Yuji , Passos, João F. , Pignolo, Robert J. , Doolittle, Madison, Tchkonia, Tamara, LeBrasseur, Nathan K , Robbins, Paul D , Niedernhofer, Laura J , Pignolo, Robert J , Khosla, Sundeep , Passos, João F , Chandra, Abhishek , Farr, Joshua N. , Tchkonia, Tamar , Monroe, David G. , Khosla, Sundeep

Mayo Clinic

Aging Cell | April 1, 2022 | Volume: 21 | Issue: 5 | Pages: No page available

10.1111/acel.13602 | PMID 35363946 Get It

Abstract Cellular senescence, which is a major cause of tissue dysfunction with aging and multiple other conditions, is known to be triggered by p16 Ink4a or p21 Cip1 , but the relative contributions of each pathway toward inducing senescence are unclear. Here, we directly addressed this issue by first developing and validating a p21 ‐ ATTAC mouse with the p21 Cip1 promoter driving a “suicide” transgene encoding an inducible caspase‐8 which, upon induction, selectively kills p21 Cip1 ‐expressing senescent cells. Next, we used the p21 ‐ ATTAC mouse and the established p16 ‐ INK ‐ ATTAC mouse to directly compare the contributions of p21 Cip1 versus p16 Ink4a in driving cellular senescence in a condition where a tissue phenotype (bone loss and increased marrow adiposity) is clearly driven by cellular senescence—specifically, radiation‐induced osteoporosis. Using RNA in situ hybridization, we confirmed the reduction in radiation‐induced p21 Cip1 ‐ or p16 Ink4a ‐driven transcripts following senescent cell clearance in both models. However, only clearance of p21 Cip1 +, but not p16 Ink4a +, senescent cells prevented both radiation‐induced osteoporosis and increased marrow adiposity. Reduction in senescent cells with dysfunctional telomeres following clearance of p21 Cip1 +, but not p16 Ink4a +, senescent cells also reduced several of the radiation‐induced pro‐inflammatory senescence‐associated secretory phenotype factors. Thus, by directly comparing senescent cell clearance using two parallel genetic models, we demonstrate that radiation‐induced osteoporosis is driven predominantly by p21 Cip1 ‐ rather than p16 Ink4a ‐mediated cellular senescence. Further, this approach can be used to dissect the contributions of these pathways in other senescence‐associated conditions, including aging across tissues.
P149. EVALUATING THE IMPACT OF BREAST AND NIPPLE SENSATION ON QUALITY-OF-LIFE AFTER NIPPLE-SPARING MASTECTOMY WITH IMPLANT RECONSTRUCTION: LONG-TERM OUTCOMES UTILIZING BREAST-Q
Armstrong, Valerie, Rebecca, Alanna M. , Casey, William J., Kruger, Erwin A., Pockaj, Barbara A. , Teven, Chad M. , Hammond, Jacob B. , Kandi, Lyndsay A. , Kosiorek, Heidi , Cronin, Patricia A.

Mayo Clinic

Plastic and Reconstructive Surgery - Global Open | April 1, 2022 | Volume: 10 | Issue: 4S | Pages: 120-121

10.1097/01.gox.0000828936.95640.05 Get It

P154. FACIAL SURGERY SCARRING IMPACT ON QUALITY-OF-LIFE: THE PERSPECTIVES OF ASIAN AND CAUCASIAN PATIENTS
Garg, Stuti P. , Wan, Rou , Weissman, Joshua P. , Lang, Lin, Dumanian, Gregory A. , Kim, John YS , Reddy, Narainsai K. , Ellis, Marco F. , Galiano, Robert D.

Mayo Clinic

Plastic and Reconstructive Surgery - Global Open | April 1, 2022 | Volume: 10 | Issue: 4S | Pages: 122-123

10.1097/01.gox.0000828956.04140.24 Get It

P156. OPTIMIZING OUTCOMES IN THE MANAGEMENT OF STAGE III AND IV PRESSURE ULCERS
Saleem, Humza Y. , Moran, Steven L. , Vyas, Krishna S. , Thongprayoon, Charat

Mayo Clinic

Plastic and Reconstructive Surgery - Global Open | April 1, 2022 | Volume: 10 | Issue: 4S | Pages: 123-123

10.1097/01.gox.0000828964.12056.00 Get It

P98. HOME SWEET HOME: THE INTEGRATED PLASTIC SURGERY RESIDENCY MATCH DURING THE COVID-19 PANDEMIC
Antezana, Luis A. , Muro-Cardenas, Jose , Xie, Katherine , Weissler, Jason M., Bakri, Karim , Antezana, Luis , Rode, Matthew M. , Bakri, Karim

Mayo Clinic

Plastic and Reconstructive Surgery - Global Open | April 1, 2022 | Volume: 10 | Issue: 4S | Pages: 96-96

10.1097/01.gox.0000828740.31707.12 Get It

P107. COMPARISON OF CHEST FEMININITY OF TRANSGENDER WOMEN WITH HORMONE TREATMENT VS. SURGICALLY AUGMENTED WITH BREAST IMPLANTS
Zhu, Agnes , Callori, Steven , Hebel, Nathan , Martinez‐Jorge, Jorys, Boonipat, Thanapoom

Mayo Clinic

Plastic and Reconstructive Surgery - Global Open | April 1, 2022 | Volume: 10 | Issue: 4S | Pages: 100-101

10.1097/01.gox.0000828776.79912.0c Get It